Health & Research Goals
Hormone Reset
Reinicio Hormonal
High-Performance Stack
Select a vial or the total
Primary Description
Kisspeptin stimulates GnRH release, promoting endogenous LH and FSH. PT-141 acts on melanocortin-4 receptors. Ipamorelin maintains growth hormone pulsatility. Triple-axis hormonal signaling protocol for hormone optimization research.
Demonstrated Effects
- Combined synergistic effect
- Maximized research outputs
- Pre-verified protocol
Proposed Mechanisms of Action
Combined Mechanism
Kisspeptin-10 is the master HPG axis activator — it binds KiSS1R/GPR54 receptors in GnRH neurons, triggering potent pulsatile GnRH release and downstream LH/FSH surge. This restores the hormonal prerequisite for endogenous testosterone, estrogen, and progesterone production — the first step in hormonal reset. PT-141 (Bremelanotide) bypasses the hormonal pathway entirely: it activates MC3R and MC4R melanocortin receptors in the hypothalamus to directly enhance sexual desire, arousal, and erectile function through the CNS — independent of circulating sex hormone levels. Ipamorelin stimulates selective GH release via GHS-R1a, supporting the anabolic and tissue recovery environment required during hormonal restoration.
Stack Compounds
Research Evidence & Clinical Data
Research Profile
Kisspeptin stimulates GnRH release upstream of LH/FSH. PT-141 acts on melanocortin-4 receptors. Ipamorelin maintains GH pulsatility. Triple-axis hormonal signaling protocol.
Safety Profile
Common Side Effects
- PT-141 may cause transient nausea (dose-dependent) — start at 0.5mg to assess tolerance
- Transient blood pressure elevation with PT-141 — monitor in hypertensive patients
- Facial flushing and headache common within 30-60 minutes of PT-141 injection
- Kisspeptin may transiently elevate LH/FSH beyond normal range — monitor hormone panel
- Do not combine PT-141 with PDE5 inhibitors without medical supervision
Contraindications
- Cardiovascular disease or uncontrolled hypertension (PT-141)
- Hormone-sensitive tumors (estrogen/testosterone-dependent cancers)
- Pregnancy or lactation
- Severe renal or hepatic impairment
Analytical Quality Assurance
Research Protocols
Dosing Protocols
Combined Research Protocol: Reinicio Hormonal
Sub-QMonitoring & Risk Management
Compound Stack Monitoring
For stacks and blends, refer to the individual compound monographs for each included ingredient for specific monitoring guidelines.